Cytogenetic Investigation of Canine Soft Tissue Sarcomas, Histiocytic Malignancies and Hemangiosarcoma

Matthew Breen PhD., C.Biol., M.I.Biol - Principal Investigator
NCSU College of Veterinary Medicine

INFORMED CONSENT FOR PARTICIPANTS

Australian Shepherd

Please initial the bottom of pages 1-4 to acknowledge that you have read and understand the content and complete pages 5 and 6. All six pages should be submitted to Dr. Breen with the samples being submitted.

1) Who is conducting the study?
   This study involves research being conducted by Dr. Matthew Breen and Dr. John Cullen at the College of Veterinary Medicine, North Carolina State University. The study is funded by the American Kennel Club Canine Health Foundation (award number 760).

2) Why is this study being done?
   It has been established that non-random chromosome aberrations are characteristic of specific types of many different human cancers. The knowledge of such aberrations has identified areas of the human genome to be targeted for further research. In the dog, the extent and identity of chromosome aberrations associated with specific cancers are still largely unknown. Soft tissue sarcomas in dogs are relatively rare, occurring at a frequency of approximately 1%. However, in certain breeds, such as the Flat-Coated Retriever and Bernese Mountain Dog, soft tissue sarcomas account for up to 50% of all malignant tumors and thus represent a serious health and welfare issue for those breeds. Histiocytic malignancies and hemangiosarcoma are also prevalent in these two breeds as well as Golden Retrievers, German Shepherds and Briards. These tumors are difficult to classify by conventional methods alone and so attention is required to develop improved modes of diagnosis. In humans, sarcomas have been demonstrated to be associated with specific chromosomal aberrations that have been shown to have both diagnostic and prognostic significance. This CHF funded project is using major recent advances in canine molecular cytogenetics to identify recurrent chromosome aberrations associated with canine soft tissue sarcomas, in particular those of histiocytic origin. This project will identify areas of the canine genome associated with such cancers for further investigation at the sub-chromosomal level.

   Only Flat-Coated Retrievers, Bernese Mountain Dogs, Golden Retrievers, German Shepherds Briards and Australian Shepherds are eligible for inclusion into this study without prior approval of the P.I.

3) How will this study involve my dog?
   If your dog is diagnosed with a soft tissue sarcoma (diagnosis must be made by a licensed veterinarian) or is a first-degree relative (parent, sibling, offspring) of a dog diagnosed with a

Owner’s or Agent’s Initials _______
Informed Consent Form rev 01/08
Cytogenetic Investigation of Canine Soft Tissue Sarcomas, Histiocytic Malignancies and Hemangiosarcoma

soft tissue sarcoma, we are asking for you to allow your dog to participate in this study.
For dogs diagnosed with a soft tissue sarcoma, hemangiosarcoma or histiocytic malignancy, participation will involve obtaining a small blood sample (10-20ml) and two samples of the tumor, one in formalin and one in a sterile container. All three samples will be used for research purposes. In general your veterinarian will take a sample of the tumor as part of the routine diagnostic procedure. We ask that some of this tumor also be sent to us for use in this study. We also require a copy of the official pedigree of your dog and a copy of any pathology report relating to the tumor.

For dogs with a first-degree relative that has been diagnosed with soft tissue sarcoma, hemangiosarcoma or histiocytic malignancy, participation will require the submission of a small EDTA blood sample (10-20ml), which may be taken by your veterinarian during your dog’s annual health examination, a copy of the official pedigree and a copy of the pathology report relating to the diagnosis of the tumor in the first degree relative (you should be able to obtain this from your veterinarian).

NO ADDITIONAL TISSUE WILL BE REQUIRED FROM RELATIVES UNLESS THEY DEVELOP A SOFT TISSUE SARCOMA, HEMANGIOSARCOMA OR HISTIOCYTIC MALIGNANCY.

4) What is the possible discomfort or risk of allowing my dog to join the study?
Participation in this study will pose no additional discomfort or risk to your dog beyond that associated with the elective surgical procedure for tumor biopsy or removal. There are no foreseeable risks to the health, comfort, or lifespan of your dog that may arise from the use of the donated cells and tissues in the laboratory.

5) What are the potential benefits, if any, from joining this study?
Individual dogs will derive no direct benefit from participating in this study. Their care and treatment will be no different to that provided to cancer patients that are not included in this study. The results from this study may improve the outcome and quality of life of dogs with cancer in the future. Moreover, an improved understanding of the genetic basis of canine cancer may also lead to recommendations for judicious breeding practices and prevention strategies.

6) How long will the study continue?
The study is part of an ongoing study that has been funded since 2004. We anticipate recruitment of new cases will continue until at least December 2008.

7) What will happen to the information the study keeps on my dog?
Donation of blood and tumor tissues from your dog will remain strictly confidential. Any publication or communication of results of any and all experiments performed with these materials will protect the anonymity of the donor. The AKC Canine Health Foundation may inspect the records for accuracy and scientific integrity.

8) What will happen if I change my mind?
Allowing your dog to participate in this study is voluntary. However, by this consent, you agree to relinquish the rights to the cells, tissues, and any experimental results derived from their use for this

Owner’s or Agent’s Initials _______
9) **Are there reasons why my dog may be excluded from the research?**

If the investigators cannot confirm the diagnosis of soft tissue sarcoma using routine diagnostic procedures (analysis of the biopsy or additional special tests on the tumor), or if samples are acquired or shipped in a manner inconsistent with that described in the Procedures for Enrollment (attached), your dog may be excluded from the study. In the event that this was to happen, you will be notified. In addition, the principal investigator, Dr. Matthew Breen has the right to terminate this study at any time for any reason.

10) **Are there costs that I will be expected to pay?**

You will be responsible for all the customary charges from your veterinarian, including those incurred for diagnosis and treatment of your dog. The study has no funding to pay for any portion of your dog’s treatment or additional tests. Owners who choose to donate blood and the surgically-removed tumors from their animals will have no financial obligations to NCSU-CVM for use of these materials for the research investigations described herein. You will be responsible for ensuring that the blood and tumor samples are sent to Dr. Breen by overnight courier and the cost associated with this.

11) **How many dogs will be included in this study?**

We anticipate recruiting at least 100 eligible tumor samples, and paired blood samples, together with their relatives, during this study.

12) **What will my dog’s blood and tumor sample be used for?**

The tumor sample submitted in formalin will be used to verify the diagnosis and stage of the tumor. The tumor sample submitted in a sterile tube (+/- sterile transport medium) will be used obtain tumor DNA and tumor cells, which will allow us to identify chromosome aberrations associated with the tumor. The DNA obtained from the blood sample will act as a normal reference sample for that animal and will also be used to identify inherited risk factors. This will help us identify genes that impact the prognosis to conventional treatments and will generate information that may lead to strategies for prevention, as well as to development of new, more effective treatments.

13) **For how long will my dog’s samples be used?**

In addition to using your sample(s) for this study, we would like to use your samples for future studies and also share your samples with other researchers who are funded by the AKC Canine Health Foundation and/or other health-related organizations and who also seek to improve the health of dogs and humans.

These studies may include assessment of new genes that may be unknown at this time and development of treatments based on characteristics peculiar to these tumors.

Please indicate below (with your initials) your decision regarding the use of your samples.

_____ I approve the use of my sample(s) for this study, as well as for future studies by Drs. Breen and Cullen.

_____ I approve the sharing of my sample(s) with other P.I.’s, who are funded by AKC
14) **How will the identity of my dog’s samples be protected?**

The identity of dogs that participate in this study will not be shared with any registry. The Investigators will comply with all the customary practices of the sponsoring Parent Breed Clubs to protect the identity of every dog that participates in the study. However, you can choose to waive this and allow the Investigators to include your dog’s name (without identifying last name or kennel name) and/or picture to be included in newsletters or other informational materials.

- [ ] I approve the use of my dog’s name and/or picture for newsletters, web-based information, or other informational materials.
- [ ] I do not approve the use of my dog’s name and/or picture for newsletters, web-based information, or other informational materials.
- [ ] I reserve the right to approve the use of my dog’s name and/or picture for newsletters, web-based information, or other informational materials. If the need arises, I agree that the Investigators may contact me to explain the nature of the materials and I may choose to allow disclosure of my dog’s name and/or picture at that time.

15) **Who do I speak with if I have questions about the study?**

To obtain more information about this study, you may call

- Dr. Matthew Breen, the Principal Investigator of the study, preferably via e-mail at [CVM_K9Genomics@ncsu.edu](mailto:CVM_K9Genomics@ncsu.edu) or by telephoning the Canine Genomics Cancer Submission Line at **919-513-1466**, or by regular mail at College of Veterinary Medicine, North Carolina State University, 4700 Hillsborough Street, Raleigh, 27606.

  - Australian Shepherd breed contact is:

    Kim Monti  
    Australian Shepherd Hemangiosarcoma Liaison  
    e-mail: 4aussies_16paws@foxwoodkennel.com  
    tel: 505.890.6150

    www.foxwoodkennel.com  
    ASHGI 10-Steps Chairman  
    USASA Health & Genetics Committee
I, ____________________________________________ (enter name) have read this Consent Form.
and the nature of the research have been made clear to me. I have been given a copy of this
form. I have had an opportunity to ask questions about the project and understand that I can
ask questions at any time. I agree to allow my Australian Shepherd named,
______________________________________, to participate in this study. Furthermore, I
agree to donate to Dr. Matthew Breen of the College of Veterinary Medicine at North
Carolina State University blood and tumor tissues removed from my dog during the normal
course of diagnosis and treatment for its disease. I understand that these tissues will be used in
studies of canine cancer, and would otherwise be discarded. I also understand that by signing
this Consent Form, I give up all future claims to these tissues and any experimental results
that may be derived from their investigational use. If I have any questions or problems that I
feel are related to the study, I can contact the Principal Investigator whose name is on this
form.

Signature of Owner or Agent _______________________________________________________

Date ___ / ___ / _____  Breed of dog  AUSTRALIAN SHEPHERD

Call Name of dog ________________________________________________________________

AKC Registration number _________________________________________________________

Sex of dog _______  Date of birth ___ / ___ / ______  Age at submission ________

Name and address of owner (please print clearly)
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________

Telephone : (       )    Fax:  (      )

E-mail:
PLEASE COMPLETE EITHER SECTION A OR B

A. My dog is being submitted as a cancer patient YES / NO (please circle as appropriate) with a diagnosis of

☐ Soft tissue sarcoma
☐ Hemangiosarcoma
☐ Histiocytic malignancy (Malignant histiocytosis, histiocytic sarcoma)

Or

B. My dog is being submitted as a ____________________________________ of ____________________________

(please enter relationship)

________________________________________________________________

(please enter name of the dog already in this study)

Person Obtaining Consent ____________________________________________
(Attending veterinarian or representative)

Date _____ / _____ / _____

Name and address of Veterinarian (please print clearly)

________________________________________________________________

________________________________________________________________

________________________________________________________________

________________________________________________________________

Telephone: (     ) Fax: (     )

E-mail:

PLEASE RETURN THIS FORM TO:

Dr. Matthew Breen
Soft Tissue Sarcoma Project
NCSU College of Veterinary Medicine
CVM Research Building (Room 330)
4700 Hillsborough Street
Raleigh, NC 27606
Tel. 919-513-1466 Fax: 919-513-7301

Owner’s or Agent’s Initials _______